Apoptosis and cell cycle-related genes and proteins in classical Hodgkin lymphoma: Application of tissue microarray technique

Applied Immunohistochemistry and Molecular Morphology

Volumn 11, Issue 3, 2003, Pages 206-213

  Wang, Jinfen ^a   Taylor, Clive R ^b  

^a SHANXI TUMOR HOSPITAL   (China)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Apoptosis; Cell cycle; EBV; Hodgkin lymphoma; Reed Sternberg cells; Tissue microarray

Indexed keywords

CD15 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CELL CYCLE PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); EPITHELIAL MEMBRANE ANTIGEN; LATENT MEMBRANE PROTEIN 1; MONOCLONAL ANTIBODY KI 67; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; VIRUS RNA;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CELL CYCLE; CHILD; EPSTEIN BARR VIRUS; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; RNA PROBE; VIRUS DETECTION;

EID: 0042316753     PISSN: 15412016     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129039-200309000-00002     Document Type: Article

References (59)

1. Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumors: pathology and genetics: tumors of haematopoietic and lymphoid tissue. Lyon, France: IARC Press, 2001.
2. Isaacson P, Ashton-Key M. Phenotype of Hodgkin and Reed-Sternberg cells. Lancet. 1996;347:481-94.
3. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a colonel expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337:453-8.
4. Mason DY, Banks P, Chan J, et al. Nodular lymphocyte-predominance Hodgkin's disease: a distinct clinicopathological entity. Am J Surg Pathol. 1994;18:526-30.
5. Taylor CR, Riley CR. Molecular morphology of Hodgkin lymphoma. Appl Immunohistochem Mol Morphol. 2001;9:187-202.
6. Taylor CR, Riley CR. Evolving concepts of the nature of Hodgkin's disease: a history. Ann Diagn Pathol. 2000;4:337-46.
7. Herbst H, Raff T, Stein H. Phenotypic modulation of Hodgkin and Reed-Sternberg cells by Epstein-Barr virus. J Pathol. 1996;179:54-9.
8. Weinreb M, Day PJ, Niggli F, et al. The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas. Arch Dis Child. 1996;74:27-31.
9. Herbst H, Steinbrecher E, Niedobitek G, et al. Distribution and phenotype of Epstein-Barr virus-harbouring cells in Hodgkin's disease. Blood. 1992;80:484-91.
10. Shimazaki K, Ohshima K, Hstsoks S, et al. Accessory cell tumour: a clinicopathological study of 16 aggressive tumors containing EBV-positive Hodgkin and Reed-Sternberg-like giant cells. Histopathology. 2002;40:12-21.
11. Jan S, Margareta A, Carlos G, et al. Expression of the signal transduction molecule (zeta) in peripheral and tumor-associated lymphocytes in Hodgkin's disease in relation to the Epstein-Barr Virus status of the tumor cells. Br J Haematol. 2002;116:765-73.
12. Weiss LM, Movahed LA, Warnke RA, et al. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med. 1989;320:502-6.
13. Shimazaki K, Ohshima K, Haraoka S, et al. Accessory cell tumour: a clinicopathological study of 16 aggressive tumours containing EBV-positive Hodgkin and Reed-Sternberg-like giant cells. Int J Oncol. 2000;17:603-9.
14. Chu WS, Aguilera NS, Wei MQ, et al. Anti apoptotic marker Bcl-X(L), expression on Reed-Sternberg cells of Hodgkin's disease using a novel monoclonal marker, YTH-2H12. Hum Pathol. 1999;30:1065-70.
15. Benharroch D, Levy A, Prinsloo I, et al. Apoptotic index as a prognostic factor in Hodgkin's disease. Leuk Lymphoma. 1999;33:351-9.
16. Izban KF, Ergin M, Huang Q, et al. Characterization of NF-KappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-KappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod Pathol. 2001;14:297-310.
17. Rigal-Huguet F, Gopas J, Prinsloo I, et al. Frequent expression of the cell-death inducing gene bax in Reed-Sternberg cells of Hodgkin's disease. Blood. 1996;87:2470-5.
18. Chen W-G, Chen Y-Y, Kamel OW, et al. p53 mutations in Hodgkin's disease. Lab Invest. 1996;75:519-2.
19. Lorenzen J, Hansmann M-L, Pezella F, et al. Expression of bcl-2 oncogene product and chromosomal translocation t(14;18) in Hodgkin's disease. Hum Pathol. 1992;23:1205-9.
20. Schlaifer D, Krajewski S, Rigal-Huguet F, et al. Bcl-x gene expression in Hodgkin's disease. Leuk Lymphoma. 1996;23:143-6.
21. Schlaifer D, March M, Kajewski S, et al. High expression of the bcl-x gene in Reed-Sternberg cells of Hodgkin's disease. Blood. 1995;85:2671-4.
22. Stetler-Stevenson M, Crush-Stanton S, Cossman J. Involvement of the bcl-2 gene in Hodgkin's disease. J Natl Cancer Inst. 1990;82:855-8.
23. Trüper LH, Brady G, Bagg A, et al. Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations. Blood. 1993;81:3097-115.
24. Wan WH, Fortuna MB, Furmanski P, et al. A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J Immunol Methods. 1987;103:121-9.
25. Lampkin SR, Allred DC. Preparation of paraffin blocks and sections containing multiple tissue samples using a skin biopsy punch. J Histotechnol. 1990;13:121-3.
26. Packeisen J, Buerger H, Krech R, et al. Tissue microarray: a new approach for quality control in immunohistochemistry. J Clin Pathol. 2002;55:613-5.
27. Skacel M, Skilton B, Pettay JD, et al. Tissue microarray: a powerful tool for high-throughput analysis of clinical specimens. Appl Immunohistochem Mol Morphol. 2002;10:1-6.
28. Nocrro A, Lononen J, Kallioniemi O, et al. Tissue microarrays (TMAS) for high-throughput molecular pathology research. Int J Cancer. 2001;94:1-5.
29. Abele MC, Valente G, Kerim S, et al. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease: an immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies. Haematologica. 1997;82:281-5.
30. Sanchez-Beato M, Martinez-Montero JC, Doussis-Anagnostopoulou TA, et al. Anomalous retinoblastoma protein expression in Sternberg-Reed cells in Hodgkin's disease: a comparative study with p53 and Ki67 expression. Br J Cancer. 1996;74:1056-62.
31. Shi Sh-R, Guo J, Taylor CR, et al. Antigen retrieval techniques: immunohistochemistry and molecular morphology. Natick, MA: Eaton Publishing, 2002.
32. Morente MM, Piris MA, Abraira V, et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood. 1997;90:2429-36.
33. Kanvaros P, Stefanaki K, Vlachonikolis J, et al. Expression of p53, p21/waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin's lymphomas, Histol Histopathol. 2000;15:445-53.
34. Xu JL, Lai R, Kinoshita T, et al. Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol. 2002;55:530-4.
35. Hirabauashi S, Machi S, Maebashi K, et al. Immunohistochemical detection of DNA topoisomerase type II (alpha) and Ki-67 in adenoid cysticcarcinoma and pleomorphic adenoma of the salivary gland. J Oral Pathol Med. 1999;28:131-6.
36. Villman K, Stahl E, Liljegren G, et al. Tipoisomerase II-α expression in different cell cycle phases in fresh human breast carcinomas. Mod Pathol. 2002;15:486-91.
37. Wilson CS, Medeiros J, Lai R, et al. DNA tipoisomerase IIα in multiple myeloma: a marker of cell proliferation and not drug resistance. Mod Pathol. 2001;14:886-91.
38. Kancherta RR, Nair JS, Ahmed A, et al. Evaluation of topotecan and etoposide for non-Hodgkin lymphoma. Cancer. 2001;91:463-71.
39. Harper JW, Adami GY, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor G1 cyclin-dependent kinase. Cell. 1993;75:805-16.
40. Waga S, Hannon GJ, Beach D, et al. The p21 inhibitor of cyclin-dependent kinase controls DNA replication by interaction with PCNA. Nature. 1994;369:574-8.
41. WAF1/CIP1, wild type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease. J Pathol. 1996;180:58-64.
42. Koichi O, Seiji H, Takehiro F, et al. Expressions of cyclin E, A, and B1 in Hodgkin and Reed-Sternberg cells: not suppressed by cyclin-dependent kinase inhibitor p21 expression. Pathol Int. 1999;49:506-12.
43. Stefanaki K, Tzard M, Kouvidou CH, et al. Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue. Anticancer Res. 1998;18:2403-8.
44. Montesinos-Rongen M, Roers A, Küppers R, et al. Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternber cells in Hodgkin's disease. Blood. 1999;94:1755-60.
45. Said JW, Barrera R, Shintaku IP, et al. Immunohistochemical analysis of p53 expression in malignant lymphomas. Am J Pathol. 1992;141:1343-8.
46. Lauritzen AF, Hou-Jensen K, Ralfkiaer E. p53 Protein expression in Hodgkin's disease. APMIS. 1993;101:689-94.
47. Doussis IA, Pezzella F, Lane DP, et al. An immunocytochemical study of p53 and bcl-2 protein in Hodgkin's disease. Am J Clin Pathol. 1993;99:663-7.
48. Trümper LH, Brady G, Bagg A, et al. Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations. Blood. 1993;81:3097-115.
49. Xerry L, Parc P, Bouabdallah R, et al. PCR-mismatch analysis of p53 gene mutation in Hodgkin's disease. J Pathol. 1995;175:189-94.
50. Villuendas R, Pezzella F, Gatter K, et al. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21- immunophenotype associated with missense p53 mutations. J Pathol. 1997;181:51-61.
51. Sánchez-Beato M, Martinez-Montero JC, Doussis-Anagnostopoulou TA, et al. Anomalous retinoblastoma protein expression in Sternberg-Reed cells in Hodgkin's disease: a comparative study with p53 and Ki67 expression. Br J Cancer. 1996;74:1056-62.
52. Maggio WM, Stekelenburg E, Berg AVD et al. Tp53 gene mutation in Hodgkin's lymphoma are infrequent and not associated with absence of Epstein-Barr virus. Int J Cancer. 2001;94:60-6.
53. Montesinos-Rongen M, Roers A, Roers A, et al. Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood. 1999;94:1755-60.
54. Kerr JFR, Wyllie AH, Currie AR. Apoptosis, a basic biological phenomenon with wider implications in tissue kinetics. Br J Cancer. 1972;26:239-45.
55. Wyllie AH. Glucocorticoid-induce thymocyte apoptosis is associated with endogenous endonuclease activation. Nature. 1980;284:555-6.
56. Cohen GM, Sun XM, Snowden RT, et al. Key morphological feature of apoptosis may occur in the absence of internucleosomal DNA fragmentation. Biochem J. 1992;286:331-4.
57. Smolewski P, Niewiadomska H, Los E, et al. Spontaneous apoptosis of Reed-Sternberg and Hodgkin cells: clinical and pathological implications in patients with Hodgkin's disease. Int J Oncol. 2000;17:603-9.
58. Kolar Z, Flavell JR, Ehrmann J Jr, et al. Apoptosis of malignant cells in Hodgkin's disease is related to expression of the cdk inhibitor p27KIPI. J Pathol. 2000;190:604-12.
59. Chetty R, Bickhoo A. Retinoblastoma protein and Epstein-Barr virus (EBV) expression in south African Hodgkin's disease. Hematol Oncol. 1997;15:191-5.